Abstract:Based on literature data, the estimated global fatality rate for severely ill patients with septic shock is around 40%. [ 1–3 ] The current approach to treating septic Huk involves promptly administering fluids, using vasoactive medications, and prescribing antibiotics. Nevertheless, the extended utilization of vasoactive medications can result in a lengthened duration of hospitalization and heightened death rates. [ 3–6 ] The Exercise Guidelines for Surviving Sepsis suggest using HC adjuvant therapy for individuals with severe symptoms who need a norepinephrine dose of 0.25 mg/kg/min or higher for more than 4 hours. [ 6 ] The utilization of glucocorticoids in individuals experiencing septic shock may be traced back to the 1950s. The initial modest randomized controlled studies conducted by Hahn, Weitzman, and other researchers yielded contradictory outcomes. [ 7 , 8 ] In 1987, Bone et al showed that administering high dosages of glucocorticoids to patients with severe sepsis and septic shock could lead to an elevated rate of mortality during their hospital stay. [ 9 , 10 ] In 2002, Annane et al conducted a research which demonstrated that a 7-day regimen of low-dose hydrocortisone (HC) was effective in decreasing mortality rates. [ 11 ] In 2004, the Surviving Sepsis Campaign (SSC) guideline provided recommendations for the administration of glucocorticoids for patients diagnosed with septic shock. [ 12 ] In the studies of Sprung et al [ 13 ] and Annane et al, [ 11 ] 2 Sebille trials demonstrated that the use of hydrocortisone (HC) did not result in a decrease in the death rate of patients with septic shock. [ 11 , 13 ] As a result, the guidelines from the SSC were modified from a "recommended" status in 2004 to a continued "recommended" status in 2008. In 2011, Annane, D. conducted a study along with Renault, A. et al which shown that HC-assisted treatment of sepsis resulted in a reduction in 90-day mortality to 43% compared to 49%. [ 14 ] In 2010, Fang, F. also conducted a related study. A recent small-scale randomized controlled trial (COIITSS) conducted by et al demonstrated that the use of HC may lead to a decrease in 28-day mortality. [ 15 , 16 ] Consequently, the 2021 SSC guidelines have updated their recommendation about the use of HC in patients with septic shock, now considering it a weak recommendation. [ 2 ] A meta-analysis conducted in May 2023 examined the effects of low-dose hydrocortisone (HC) on persons with septic shock. The investigation found that HC may lead to an increased risk of mortality, with a relative risk (RR) of 0.86 for 90-day mortality. [ 17 ] Based on many research, our analysis determined that the use of low-dose hydrocortisone (HC) as an additional treatment may decrease the likelihood of death during a hospital stay for patients with septic shock. However, there is no specific information available regarding when to start HC therapy. We performed a meta-analysis by gathering data from published randomized controlled trials (RCTs) and cohort studies to evaluate the effects of starting low-doses of hydrocortisone (HC) at various time intervals on the clinical outcomes of patients with septic shock.

Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock

Effects and Safety of Separate Low-Dose Hydrocortisone Use in Patients with Septic Shock: A Meta-Analysis

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation

Effect of hydrocortisone-fludrocortisone combination on mortality in septic shock: a systematic review and meta-analysis

Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Hydrocortisone plus Fludrocortisone for Adults with Septic Shock

Corticosteroid Administration is Associated with Improved Outcome of Patients Presenting High Inflammatory Cytokine Levels During Septic Shock

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

[Therapeutic effect of hydrocortisone combined with vitamin C and vitamin B1 on patients with sepsis: a Meta-analysis]

Early use of low-dose hydrocortisone can reduce in-hospital mortality in patients with septic shock: A systematic review and meta-analysis

Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients with Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center

Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial

Early administration of hydrocortisone, vitamin C, and thiamine in adult patients with septic shock: a randomized controlled clinical trial

Evaluating the Efficacy and Side Effects of Corticosteroid Therapy in Severely ill COVID-19 Patients

Rapid uptake of adjunctive corticosteroids for critically ill adults with septic shock following publication of ADRENAL trial. A multicenter, retrospective analysis of prescribing practices in Queensland Intensive Care Units

Hydrocortisone Combined with Vitamin C and Thiamine in the Treatment of Sepsis/Septic Shock: A Systematic Review with Meta-Analysis and Trial Sequential Analysis

Corticosteroid in Non-Covid-19 Induced Community-Acquired Pneumonia, a Meta-Analysis.

Efficacy and Safety of Hydrocortisone, Ascorbic Acid, and Thiamine Combination Therapy for the Management of Sepsis and Septic Shock: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

The Timing of Initiating Hydrocortisone and Long-term Mortality in Septic Shock

Combination therapy of thiamine, vitamin C and hydrocortisone in treating patients with sepsis and septic shock: a meta-analysis and trial sequential analysis

Why the Adjunctive Corticosteroid Treatment in Critically Ill Patients With Septic Shock (ADRENAL) Trial Did Not Show a Difference in Mortality?